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EXPERT OPINION
Abstract: Many atypical antipsychotic medications are becoming available for clinical use.
Ziprasidone is a recent addition to this group and is expected to become available for clinical
use in Canada in 2005. Ziprasidone has some significant differences compared with other
atypicals currently available in Canada. Clinicians need to understand the benefits and risks
associated with each of the antipsychotic medications available for the treatment of
schizophrenia and related psychotic disorders to ensure their most appropriate utilization. At
the suggestion of Professor Stan Kutcher (chair) and as part of an ongoing commitment to
provide independent education pertaining to the utility of new psychotropic compounds to
health professionals, a panel of Canadian experts in the treatment of schizophrenia spectrum
disorders was convened to provide consensus suggestions for the appropriate clinical use of
ziprasidone. The consultations regarding the development of these recommendations were
organized by Brainworks International (BWI) with arms-length funding from Pfizer Canada.
This paper describes the experts’ consensus views on the efficacy and safety of ziprasidone,
their suggestions on which patients may be suitable for ziprasidone treatment, and how to
initiate treatment (including how to switch from other antipsychotic medications), manage
side effects, and monitor patients in long-term therapy. These suggestions are those of the
authors only and are not endorsed by or necessarily reflect the opinions of BWI or Pfizer
Canada.
Keywords: schizophrenia, treatment, ziprasidone, consensus, schizoaffective, atypical
antipsychotic, psychosis
Introduction
Schizophrenia and related psychotic disorders, such as schizoaffective disorder,
schizophreniform disorder, and psychotic disorder not otherwise specified (NOS),
are serious brain disorders characterized by disturbances in cognition, perception,
behavior, mood, and functioning, which collectively affect approximately one percent
of the population (Eaton 1985; Bhalla 2004; Brannon 2004). The onset of these
disorders is typically in late adolescence or early adulthood (Haefner and an der
Heiden 1997), and the longitudinal course often involves relapses, deterioration in
functioning, and chronicity. These disorders can be associated with significant
comorbidity, including substance abuse, depression, and suicide (Cassano et al 1998).
As a result, schizophrenia and related psychotic disorders impose tremendous burden
on the individuals affected, their families (Thompson and Doll 1982), and society
(Murray and Lopez 1996; Goeree 1999). Treatment includes pharmacological and
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psychosocial interventions; antipsychotic medication is
necessary but is not sufficient as a treatment strategy. Clinical
outcomes can only be optimized by ensuring that
antipsychotic medications are rationally and appropriately
used, within the context of best available rehabilitation
interventions.
The discovery in 1952 of the antipsychotic properties
of chlorpromazine and the subsequent development of
numerous other conventional antipsychotics represented a
major advance in the treatment of psychotic disorders.
Although these medications have similarly good efficacy
in treating positive psychotic symptoms such as delusions
and hallucinations, their efficacy in treating negative
symptoms (eg, anhedonia, avolition, and alogia) and
cognitive impairment is typically unsatisfactory.
Furthermore, these medications are associated with
significant adverse effects, particularly extrapyramidal
symptoms (EPS) (eg, parkinsonism, dyskinesia, and
akathisia). Side effects such as EPS, sedation, weight gain,
and sexual dysfunction, are an important determinant of poor
adherence to medication (Fleischhacker et al 1994; Weiden
et al 2004) which, in turn, is associated with relapse and
poorer outcome (Verdoux et al 2000). The development of
antipsychotic medications that are more effective, safer, and
better tolerated has therefore remained an important goal.
Since the introduction of clozapine (considered the
prototype of the atypical antipsychotics) three other atypical
antipsychotics – risperidone, olanzapine, and quetiapine –
have become available in Canada. Two additional agents –
ziprasidone and aripiprazole – are available in the USA, and
ziprasidone is likely to become available on the market in
Canada in 2005. All of the atypical antipsychotics have
demonstrated efficacy in the treatment of schizophrenia but
have somewhat different pharmacokinetics, pharmaco-
dynamics, and side effect profiles. When a new medication
is introduced into the market, it is important for clinicians
to be provided with clinically relevant information based
on available evidence and independent of pharmaceutical
company detailing, to ensure the most appropriate use of
the new compound and thereby optimize treatment outcome.
One way in which to fulfil this need for information is to
convene a panel of experts familiar with a given new
compound and use their expertise to create clinically
meaningful suggestions for its use.
This paper is the result of a consensus meeting attended
by Canadian experts in schizophrenia spectrum disorders.
The goal of the meeting and of this paper was to create a set
of practical, clinically relevant suggestions for clinicians
on the appropriate use of ziprasidone for the treatment
of schizophrenia and related psychotic disorders
(schizoaffective disorder, schizophreniform disorder, and
psychotic disorder NOS).
Method
At the request of Brainworks International (an independent
company dedicated to mental health associated clinical
research and education for health professionals), Pfizer
Canada agreed to fund a meeting of a Canadian group of
experts in the treatment of schizophrenia and related
psychotic disorders. Fourteen invitees were selected by
Professor Stan Kutcher (chair) for their regionally or
nationally recognized authority in the field of schizophrenia
spectrum disorders. Their clinical expertize, research
experience with ziprasidone, publications in treatment
research, and involvement in the development of regional
or national guidelines on schizophrenia and related psychotic
disorders were factors in their selection. Additionally, a
pharmacist and a cardiologist were invited to give their
expert perspectives on particular topics. These two
specialists and eight of the schizophrenia experts accepted
their invitations. Prior to the meeting, all ten experts were
asked to prepare written and oral presentations on a topic
chosen by the chair.
The consensus meeting took place on November 3rd,
2003, in Halifax, Nova Scotia. An independent medical
writer recorded the proceedings. Three observers from the
meeting sponsor attended but did not participate in the
presentations. Seven presentations were made that
collectively encompassed the safety and efficacy of
ziprasidone and suggestions for its practical clinical use.
Each presentation was followed by group discussion. The
schizophrenia experts were then divided into two subgroups,
and each subgroup was charged with identifying practical
clinically relevant suggestions for clinicians addressing the
following: when to consider the use of ziprasidone; how to
initiate ziprasidone treatment (including switching from
another antipsychotic medication and how to use injectable
ziprasidone); and important aspects of monitoring of
ongoing treatment with ziprasidone. The subgroups
presented their suggestions for discussion and a group
consensus was reached. Three further presentations reviewed
receptor affinity research, advantages and disadvantages of
all available atypical antipsychotics, and a cardiology
perspective on ziprasidone’s prolongation of the QTcNeuropsychiatric Disease and Treatment 2005:1(2) 91
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interval. The meeting closed after a final group discussion
on the implications of this information for clinicians.
The independent medical writer drafted a consensus
statement based on the proceedings of the meeting and
available literature on ziprasidone. The draft statement was
circulated to all attendees for their comments. Revisions
were made accordingly and revised drafts were recirculated
to give attendees opportunities to make changes to the
manuscript. Submission of the manuscript for publication
followed written confirmation by each of the authors as to
their agreement with all of the information found in the
paper.
Practical summary of atypical
antipsychotic drugs
Although individual patient responses are varied, both
conventional and atypical antipsychotics are reasonably
effective at controlling the positive symptoms of
schizophrenia (including delusions, hallucinations, thought
disorder, and behavioral dysinhibition). Selected atypicals
(ie, risperidone and olanzapine) have shown a small
advantage (effect size ≈ 0.2) over conventional agents in
treating negative symptoms (Geddes et al 2000; Rosenheck
et al 2003), while findings from research on mood and
cognition have been inconsistent (Meltzer and McGurk
1999; Harvey and Keefe 2001; Rosenheck et al 2003). The
atypical agents are considerably less likely than conventional
agents to cause EPS (Wright and O’Flaherty 2003) and,
with the exception of risperidone, also less likely to cause
hyperprolactinemia (and its sequelae, which can include
amenhorrhea, galactorrhea, menorrhagia, and sexual
dysfunction). However, these advantages may be somewhat
offset by the propensities of the atypical antipsychotics to
cause a metabolic syndrome characterized by substantial
weight gain, elevations in glucose and lipid plasma levels,
increased risk of type II diabetes (Lebovitz 2003), and
possibly cardiovascular disease (Allison et al 1999).
Clozapine and olanzapine are particularly associated with a
high risk of substantial weight gain and increases in serum
triglyceride levels (Allison et al 1999; Osser et al 1999;
Atmaca et al 2003; Kelly et al 2003). Quetiapine and
risperidone appears to be less problematic than clozapine
and olanzapine in this respect (Allison et al 1999; Atmaca
et al 2003), but risperidone is more prone to cause problems
related to sexual functioning, EPS, and hyperprolactinemia
(Simpson and Lindenmayer 1997; Mullen et al 2001).
Pharmacology
Pharmacodynamics of ziprasidone
Most of the efficacy of antipsychotic agents in improving
positive symptoms can be attributed to blockade of
dopaminergic D2 receptors in the mesolimbic and
mesocortical systems. To varying extents, antipsychotic
agents also antagonize D2 receptors in the nigrostriatal
pathway and tuberoinfundibular pathways, which can result
in EPS and hyperprolactinemia, respectively. The
mechanisms underlying the lower propensity of atypical
antipsychotics to cause these particular adverse events are
not fully understood and may differ for different atypicals
(Kapur 1996; Reynolds et al 1997). The original postulate
stated that it was due to atypicals’ strong antagonism of
5-HT2 receptors (Meltzer et al 1989). More recently, it has
been proposed that atypicals spend less time blocking D2
receptors than conventional agents, and thereby give way
more readily to dopamine (Kapur and Seeman 2001). In
this respect, however, there are differences among the
atypicals. Clozapine and quetiapine bind relatively loosely
to D2 receptors, whereas risperidone and olanzapine bind
more tightly. Atypicals’ affinities for 5-HT receptors are
nevertheless implicated in bringing about moderately
improved negative symptom relief, enhanced modulation
of mood, and cognitive improvement. Other side effects
common to atypicals such as anticholinergic effects (eg,
blurred vision, constipation, urinary retention, and
confusion), metabolic effects (eg, weight gain), and postural
hypotension are attributed to their antagonism of muscarinic
(M1), histaminic (H1), and alpha adrenergic (α1) receptors,
respectively. Differences among the various atypicals in the
strengths with which they antagonize these receptors result
in differences in their propensities to cause these various
side effects.
Ziprasidone demonstrates in vitro binding affinities for
D2 and 5-HT2A receptors similar to those of risperidone and
stronger than those of olanzapine, clozapine, and quetiapine
(Goodnick 2001). Ziprasidone’s in vitro 5-HT2A/D2 receptor
binding ratio (approximately 8:1) exceeds that of
risperidone, olanzapine, quetiapine, and aripiprazole
(Tandon et al 1997; Stahl and Shayegan 2003). In human
brain tissue, ziprasidone exhibits strong antagonism of
5-HT2C and 5-HT1D, receptors. Uniquely, it also has strong
agonist activity at 5-HT1A receptors (Seeger et al 1995) and
moderately inhibits synaptic reuptake of serotonin and
norepinephrine (Zorn et al 1995). This suggests thatNeuropsychiatric Disease and Treatment 2005:1(2) 92
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ziprasidone may have moderate antidepressant effects. Its
agonism of 5-HT1A receptors has also been hypothesized to
prevent insulin resistance (Goodnick 2001). Like quetiapine
and olanzapine, ziprasidone has lower affinity for α1
receptors than risperidone and clozapine, suggesting a lower
propensity to cause postural hypotension. Ziprasidone’s low
antagonistic activity at H1 receptors and its very weak
antagonistic activity at M1 receptors are both lower than
risperidone, olanzapine, quetiapine, and clozapine (Schmidt
et al 1998), suggesting reduced likelihood of causing
anticholinergic and metabolic side effects.
Pharmacokinetics of ziprasidone
Two formulations of ziprasidone are currently available in
the USA: an intramuscular (IM) formulation (ziprasidone
mesylate) indicated for rapid control of acute agitation in
patients with schizophrenia; and an oral formulation
(ziprasidone hydrochloride) indicated for both acute and
long-term management of schizophrenia. Time to maximum
serum concentration for oral ziprasidone is 6–8 hours, and
steady-state concentrations are achieved after 2–3 days
(Wilner et al 2000). IM ziprasidone attains peak
concentration within approximately 30 minutes (Miceli et
al 1998). Ziprasidone is extensively metabolized, with less
than 1% and 4% being excreted unchanged in urine and
faeces, respectively (Prakash et al 1997). In vitro studies
(Prakash et al 2000; Kamel et al 2002) and quantitative
excretion data analysis in short-term studies of healthy
volunteers (Prakash et al 1997; Miceli, Anziano, et al 2000;
Miceli, Smith, et al 2000) suggest that ziprasidone is
metabolized by the liver, approximately two-thirds mediated
by aldehyde oxidase and one-third mediated by cytochrome
P450 isoform 3A4. Its metabolites are inactive. The
involvement of two alternate pathways in ziprasidone
metabolism reduces the potential for pharmacokinetic
interactions between ziprasidone and other drugs (Beedham
et al 2003). The mean elimination half-life of oral
ziprasidone is approximately 7 hours (range: 3–10 hours),
and that of IM ziprasidone is 2–4 hours. With the exception
of quetiapine (mean elimination half-life of 2–3 hours), these
are shorter than those of the other atypical agents: clozapine
12 hours; risperidone (and its active metabolites) 20 hours;
quetiapine 2–3 hours; olanzapine 30 hours; and aripiprazole
(and its active metabolites) 94 hours (Keck and McElroy
2002; Winans 2003).
Efficacy of ziprasidone
The efficacy of IM ziprasidone in achieving rapid control
of acute psychotic agitation has been evaluated in patients
with schizophrenia, schizoaffective disorder, and to a lesser
extent, other psychotic disorders. The efficacy of oral
ziprasidone has been evaluated as a treatment for patients
with schizophrenia and, to a lesser extent, patients with
schizoaffective disorder in the following domains: treatment
of acute psychotic exacerbation; switching from a current
antipsychotic to ziprasidone; and maintenance treatment and
relapse prevention.
Rapid control of psychotic agitation
Rapid control of agitation with IM ziprasidone has been
demonstrated in two 24-hour, randomized, double-blind,
fixed-dose studies in inpatients with acute agitation
associated with schizophrenia or another psychotic disorder.
(Approximately 50% of patients had a primary diagnosis
of schizophrenia, and 30% had a primary diagnosis of
schizoaffective disorder.) The first study (Lesem et al 2001)
compared 10 mg of IM ziprasidone (n = 63) with 2 mg of
IM ziprasidone (n = 54). The second study (Daniel et al
2001) compared 20 mg (n = 41) and 2 mg doses (n = 38). In
both studies, efficacy assessments were conducted with the
Behavioral Activity Rating Scale (BARS; Swift et al 2002)
just before the first injection and at 15, 30, 45, 60, 90, and
120 minutes after the first injection, and at hourly intervals
thereafter until the next dose or until the study end point (at
4.0 hours) if no further injections were given. Relative to
the 2 mg group, the 10 mg group showed significantly greater
improvement at 15 and 60 minutes after the first injection
(p < 0.05 in both cases) and at all subsequent time points
(p < 0.001 for the 1.5–3.5 hour time points and p < 0.01 for
the 4.0 hour time point). The 20 mg group showed
significantly greater improvement at 30 minutes (p < 0.01)
and at all subsequent time points (p < 0.001 in each case)
relative to the 2 mg group. Both the 10 mg and 20 mg groups
also yielded a significantly higher percentage of responders
(≥ 2 point BARS decrease) 2.0 hours after the first injection
(p < 0.001). At 4.0 hours post-injection, the 20 mg group
additionally yielded significantly greater improvements over
the 2 mg group on the Clinical Global Impression of Severity
Scale (CGI-S; Guy 1976a), which was used to rate agitation
rather than overall illness (p < 0.01) and on the Positive and
Negative Syndrome Scale (PANSS; Kay et al 1987) agitation
items score (p < 0.05). A cross-study analysis of the 10 mgNeuropsychiatric Disease and Treatment 2005:1(2) 93
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and 20 mg groups indicated that the efficacy of ziprasidone
was dose-related (Reeves et al 1998).
Two open-label, randomized, haloperidol-controlled
studies with inpatients with acute psychotic agitation also
support IM ziprasidone’s efficacy in the rapid control of
agitation. In a flexible-dose study (Brook et al 2000), patients
were given either 5–20 mg (maximum 80 mg/day; n = 90)
of IM ziprasidone or 2.5–10 mg of IM haloperidol
(maximum 40 mg/day; n = 42) every 4–6 hours for up to
3 days. Ziprasidone (mean [SD] dose 25.3 [18] mg/day)
yielded significantly greater reductions than haloperidol
(mean [SD] dose 8.7 [8] mg/day) in the total score of the
Brief Psychiatric Rating Scale (BPRS; Woerner et al 1988)
score and on its agitation items score (p < 0.05 in both cases),
and on the CGI-S scale (p < 0.01). In a randomized, fixed-
dose study with similar inpatients (Brook et al 2001), initial
10 mg or 20 mg doses of IM ziprasidone followed with
further doses as required (maximum of 40 mg/day for 3 days;
n = 417) were compared with initial 2.5 mg or 5 mg doses
of IM haloperidol followed with further doses as required
(maximum 10 mg/day; n = 133). Ziprasidone yielded
significantly greater improvements on the BPRS total score
and the Covi Anxiety Scale (Lipman 2001) than haloperidol
at the end of the IM phase (p < 0.01 in both cases), although
the two drugs were not differentiable on the CGI-S, number
of injections required, or number of days of injections.
Efficacy of oral ziprasidone in treating
acute psychotic exacerbation
The efficacy of oral ziprasidone over placebo in treating
acute exacerbations in cases of schizophrenia or
schizoaffective disorder has been demonstrated in a number
of 4- and 6-week randomized, double-blind studies (Keck
et al 1998, 2001; Daniel et al 1999). In one of these studies
(Daniel et al 1999), 80 mg (n = 106) and 160 mg (n = 104)
daily doses of ziprasidone were significantly better than
placebo (n = 92) in treating both positive and negative
symptoms, according to improvement scores at 6 weeks on
the PANSS total, BPRS total, BPRS core items, CGI-S, and
PANSS negative subscale scores (p < 0.05 and p < 0.001 in
all cases for the 80 mg and 160 mg groups, respectively).
The 160 mg/day dose was also significantly better than
placebo in treating symptoms of depression in patients with
clinically significant depressive symptoms at baseline (n > 50
for each treatment group) according to total scores on the
Montgomery-Asberg Depression Rating Scale (MADRS;
Montgomery and Asberg 1979; p < 0.05).
The efficacy of oral ziprasidone in treating cases of acute
psychotic exacerbation has also been compared with other
antipsychotic medications, and found to be generally similar
in efficacy. A randomized, open-label, blinded-assessment,
sequential IM/oral comparison of ziprasidone (10 mg or
20 mg IM initially with additional IM doses to 40 mg/day
for ≤ 3 days then oral 40 mg bid [twice a day] for 1 day and
oral 40–80 mg/day thereafter; n = 429) to haloperidol (2.5 mg
or 5 mg IM initially with additional IM doses to 10 mg/day
for ≤ 3 days then oral 5 mg bid for 1 day and oral
5–20 mg/day thereafter; n = 138) for the treatment of
inpatients with acute schizophrenia or schizoaffective
disorder indicated that ziprasidone’s control of symptoms
was sustained through the transition from IM to oral
formulations as effectively as that of haloperidol (Brook et
al 2001). In a 6-week, placebo-controlled, double-blind
study (Anonymous 2000), inpatients with schizophrenia or
schizoaffective disorder were randomized to either a fixed
dose of ziprasidone (40, 120, or 200 mg/day; n = 86, 76, and
82, respectively), 15 mg/day of haloperidol (n = 82) or
placebo (n = 91). Ziprasidone (at each of the 3 doses) and
haloperidol yielded statistically greater improvements
relative to placebo in BPRS total scores, PANSS total scores
and CGI-S scores (p < 0.05 and p < 0.001 in all cases for
ziprasidone and haloperidol, respectively) although only
haloperidol and the 200 mg/day dose of ziprasidone were
superior to placebo on the PANSS negative symptoms
subscale (p < 0.01 and p < 0.05, respectively). Additionally,
MADRS scores of all four groups were significantly more
improved than those of the placebo group (p < 0.01 for
120 mg/day ziprasidone and p < 0.05 in the other groups).
In an 8-week double-blind, flexible-dose study (Addington
et al 2002) with similar patients, ziprasidone (40–80 mg bid;
n = 149) was found to be as effective as risperidone (3–5 mg
bid; n = 147) on the BPRS, PANSS, MADRS, and Global
Assessment of Functioning (APA 1987) scales. The mean
daily dose was 114.2 mg for ziprasidone and 7.4 mg for
risperidone. Additionally, in similar 6-week, randomized,
flexible-dose, double-blind study (Simpson et al 2001),
ziprasidone (40–80 mg bid; n = 136) was found to be as
effective as olanzapine (5–15 mg/day; n = 133) on the BPRS,
CGI-S, PANSS, and Calgary Depression Scale for
Schizophrenia (Addington et al 1992). Ziprasidone was
titrated rapidly from 40 mg bid on days 1 and 2, to 80 mg
bid for days 3–7, before flexible dosing was allowed. The
mean daily dose was 130 mg/day for ziprasidone and 11 mg
for olanzapine.Neuropsychiatric Disease and Treatment 2005:1(2) 94
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Efficacy of ziprasidone in maintenance
treatment and relapse prevention
The efficacy of oral ziprasidone in the maintenance treatment
of stable patients with schizophrenia has been examined in
a number of longer-term studies. A 28-week, randomized,
double-blind, flexible-dose study (Hirsch et al 2002) showed
that ziprasidone (80–160 mg/day; n = 148) was as effective
as haloperidol (5–15 mg/day; n = 153) in improving positive
symptoms, symptoms of depression, and scores on the
Quality of Life Scale (Heinrichs et al 1984) in stable
outpatients with schizophrenia who required antipsychotic
medication. (Inclusion criteria included a score of ≥ 10 on
the negative subscale of the PANSS.) Respectively, only
45% and 42% of the ziprasidone and haloperidol patients
completed all 28 weeks of treatment. However, among non-
protocol violators who completed at least 14 days of therapy
and at least one post-baseline efficacy assessment (74% and
76% of all ziprasidone and haloperidol patients,
respectively), discontinuation rates due to insufficient
clinical response were the same (18%) for the two groups,
while discontinuations due to side effects were more
common for haloperidol than ziprasidone patients (18% and
8%, respectively). The study also found that ziprasidone
was significantly better than haloperidol at yielding
responders on the negative symptoms subscale of the PANSS
(defined as ≥ 20% reduction in score) at the study end point
(p < 0.05). However, ziprasidone patients’ mean change
score from baseline to study end point (with last observation
carried forward (LOCF)) on this subscale was not
significantly different from that of haloperidol patients
(mean decreases of 3.6 and 3.0, respectively).
Two double-blind, flexible-dose extension studies in
which patients with schizophrenia or schizoaffective
disorder were continued on ziprasidone or another atypical
agent – olanzapine (Simpson et al 2002) or risperidone
(Addington et al 2003) – after receiving these medications
in short-term acute exacerbation studies (Simpson et al 2001;
Addington et al 2002), provide further data on the efficacy
of ziprasidone in maintenance treatment. When interpreting
the results of these extension studies, however, it should be
noted that they pertain only to patients who completed their
initial study with a satisfactory clinical response, and agreed
to participate in the extension study. Thus, these results
should not be assumed to be generalizable to the wider group
of patients who were started on treatment in the initial study.
Given the design of these studies, they are only able to
provide upper limits on positive outcome rates and lower
limits on adverse event rates. Furthermore, to meaningfully
compare the efficacy of different medications in an extension
study, the rates and reasons for discontinuations for each
medication need to be reasonably similar to one another
during the preceding short-term study as well as during the
extension study. With these caveats in mind, these studies
indicate that in patients who already tolerated and responded
satisfactorily to their respective medication over a 6- or
8-week period, ziprasidone (80–160 mg/day) was similarly
effective as a long-term maintenance treatment as both
olanzapine (5–15 mg/day, over 20 weeks) and risperidone
(3–5 mg bid, over 44 weeks), respectively. Measures
included the BPRS, PANSS, CGI-S scale, and a clinician-
rated depression scale.
Results obtained by Kane et al (2003) in a 28-week,
randomized, double-blind study in which ziprasidone
(80–160 mg/day; n = 271) was compared with a higher
dosage range of olanzapine (10–20 mg; n = 277) in inpatients
and outpatients with schizophrenia suggested that
olanzapine had superior efficacy according to LOCF PANSS
total scores (p < 0.001), PANSS positive and negative
subscale scores (p < 0.001 and p < 0.01, respectively), and
CGI-S scores (p < 0.001). Patients for whom treatment with
olanzapine or ziprasidone was withdrawn in the preceding
6 months due to problematic adverse events or to lack of
efficacy were precluded from enrolment in the study.
Discontinuation rates due to lack of efficacy were
significantly higher for ziprasidone (13.7%) than for
olanzapine (7.2%; p < 0.05), while discontinuation rates due
to adverse events were comparable (15.1% and 11.6%,
respectively). It is possible that the titration schedule for
ziprasidone (20 mg bid for 3 days, 40 mg bid, and
incremental dose increases at weekly intervals) was not
sufficiently rapid to achieve optimal efficacy or to minimize
the occurrence of aggravated psychosis, which accounted
for 29% of its discontinuations due to adverse events.
A 1-year, randomized, double-blind, placebo-controlled
study (Arato et al 2002) of inpatients with stable, chronic
schizophrenia demonstrated that daily doses of 40 mg
(n = 72), 80 mg (n = 68), and 160 mg/day (n = 67) of
ziprasidone significantly reduced the rate of relapse over
one year from a placebo (n = 71) rate of 61% to rates of
38% (p < 0.01), 31% (p < 0.001), and 34% (p < 0.01),
respectively.
Switching patients from another
antipsychotic medication to ziprasidone
Three 6-week, open-label, blinded rater studies (Weiden,
Simpson, et al 2003) have been conducted to examineNeuropsychiatric Disease and Treatment 2005:1(2) 95
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whether differences exist in patient outcomes among three
methods of switching stable but symptomatic outpatients
with schizophrenia or schizoaffective disorder from
treatment with their current antipsychotic drug to treatment
with ziprasidone. Prior to having their medication switched,
108 patients were taking a conventional antipsychotic, 104
were taking olanzapine, and 58 were taking risperidone.
Each patient was randomized to one of the following three
switching strategies: (1) initiation of ziprasidone treatment
with immediate discontinuation of patients’ current
antipsychotic; (2) initiation of ziprasidone treatment together
with administration of the current antipsychotic for one week
at 50% of its original dose, followed by discontinuation of
the current antipsychotic after day 7; and (3) initiation of
ziprasidone treatment together with administration of the
current antipsychotic, the dose of which was tapered over
one week (100% of original dose for days 1, 2, and 3 and
50% for days 4 through 7). All groups were started on
80 mg/day of ziprasidone for 2 days followed by flexible
dosing (40–160 mg/day). Efficacy measures included the
BPRS, PANSS, and CGI-S scales.
No significant differences in outcome were observed
among the different switching strategies on any measure,
including rates of discontinuation. Data were therefore
pooled across switching strategies and the influence of the
prior medication on outcome was considered. Mean (and
SD) daily doses of ziprasidone for patients previously on
conventional antipsychotics, olanzapine, or risperidone were
respectively 91 (26), 90 (23), and 92 (24) mg/day. Total
discontinuation rates for these three groups were respectively
28%, 21%, and 21%; the respective rates of discontinuations
deemed to be due to either adverse events or inadequate
clinical response were 14.8%, 10.6%, and 10.3%. The
groups switched from conventional antipsychotics, and the
groups switched from olanzapine both showed significantly
improved scores on both the positive and negative subscales
and the total score of the PANSS at the study end point
(p < 0.01 and in all cases respectively for the two groups;
LOCF). Patients switched from risperidone also showed
significantly improved scores on the negative subscale and
the total score of the PANSS (p < 0.01 in both cases), and
their scores on the positive subscale indicated a trend of
improvement that approached statistical significance
(p = 0.08). These improvements in PANSS total scores and
subscale scores reached statistical significance for patients
switched from risperidone and from olanzapine earlier (at
or before week 2) than for patients switched from
conventional antipsychotics (for whom the differences first
reached significance at week 3). This study was not
appropriately designed to compare the efficacy of
ziprasidone to other antipsychotic agents, however. It was
limited by an open-label design, a sample selected for
suboptimal clinical response to their original medication,
opportunities for bias including regression to the mean, rater
bias, and other methodological factors may have contributed
to the observed improvements in patients’ symptoms.
Nevertheless, it does demonstrate that several switching
methods can be used when changing antipsychotic therapy
to ziprasidone in suboptimally responding patients.
Efficacy of ziprasidone with regard to
cognitive performance
A recently published report (Harvey et al 2004) indicates
that Weiden, Simpson, et al (2003) outpatients who were
switched from conventional antipsychotics (n = 108),
olanzapine (n = 104), or risperidone (n = 58) to ziprasidone
(40–160 mg/day) showed improvements in performance on
various cognitive functioning tests. Statistically significant
but modest improvements were observed on each of
three verbal learning and memory tasks (the Rey Auditory
Verbal Learning Test; Spreen and Strauss 1998) in all three
groups, although performance on a computerized spatial
learning/memory task did not change. Scores on each of
two tests of attention/vigilance (the Trailmaking Test A;
Spreen and Strauss 1998) and Digit Span Distraction Test
(DSDT; Oltmanns and Neale 1975) improved significantly
in patients switched from conventional antipsychotics, and
did not change in patients switched from olanzapine. Patients
switched from risperidone improved significantly only on
the DSDT task. Statistically significant improvements were
observed on one but not both tasks of executive functioning
(the Trailmaking Test B; Spreen and Strauss 1998 and
(Wisconsin Card Sorting Test; Heaton et al 1993) in patients
switched from either risperidone or conventional
antipsychotics; patients switched from olanzapine did not
improve on either task. Scores on one but not both tests of
verbal fluency (“category” and “letter” conditions; Spreen
and Strauss 1998) improved significantly in each of the
patient groups. Improvements in all of the tasks could be
attributable to patient selection bias, changes in patient
expectations and motivation levels, and/or practice effects,
however, and need to be replicated in prospective, double-
blind studies. Nevertheless, the results indicate that patients
requiring a change in antipsychotic therapy are unlikely to
exhibit worsening cognitive performance and may exhibit
improvements following a switch to ziprasidone.Neuropsychiatric Disease and Treatment 2005:1(2) 96
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Safety and tolerability of
ziprasidone
Considerable attention has been paid to the finding that
ziprasidone, like several other antipsychotics (thioridazine,
chlorpromazine, pimozide, and haloperidol), increases the
duration of the cardiac QT interval. The QT interval is the
time from the beginning of the QRS complex to the end of
the T wave in an electrocardiogram (ECG). The QTc interval
is the QT interval corrected for heart rate. (Values quoted in
this paper were calculated using Bazett’s correction
formula.) Normal QTc intervals are < 430 ms for males
and < 450 ms for females (Anonymous 2002). Within
individuals, mean variability in QTc interval duration over
a 24-hour period has been reported as 76 ms (SD = 19 ms,
range = 38–108 ms; n = 20 males; Morganroth et al 1991).
Prolongation of the QTc interval has been associated with
the potentially lethal paroxysmal ventricular cardiac
arrhythmia torsades de pointes, which can cause recurrent
syncope, ventricular fibrillation, and sudden death.
Clinically a QTc interval of > 450 ms is considered to be of
concern (Vieweg 2002), although a precise QTc interval at
which the risk of torsades de pointes is greatest has not been
clearly established. The vast majority of reported cases of
torsades de pointes are seen in individuals with measured
QTc intervals of ≥ 500 ms and therefore prolongation to
≥ 500 ms provides a clinically meaningful measure for the
purposes of assessing QTc risk.
In clinical development studies, 2/3095 (0.06%) of
patients receiving ziprasidone were found to have a QTc
interval > 500 ms, compared with 1/440 (0.23%) of patients
receiving placebo (Romano 2000). Across several short-term
(4–6 week), double-blind, placebo- or haloperidol-
controlled studies of ziprasidone (Keck et al 1998, 2001;
Daniel et al 1999), doses of 80–160 mg/day were associated
with mean QTc interval increases of 5–10 ms, whereas small
(< 3 ms) decreases were observed in placebo- and
haloperidol reference groups. QTc increases of > 30 ms were
observed in 13.7% of ziprasidone patients compared with
8.0% of placebo patients. For QTc increases > 60 ms, the
respective rates were 1.1% and 0.7%. However, given that
post-baseline ECG measurements were not targeted at the
time of peak drug exposure in these studies, the change in
QTc interval may have been underestimated.
In consultation with the Food and Drugs Administration
(FDA), a randomized, open-label study (Harrigan et al 2004)
was conducted to measure the effects of ziprasidone
(20–80 mg bid; n = 31), risperidone (1–8 mg bid; n = 25),
olanzapine (5–20 mg/day; n = 24), quetiapine (25–375 mg
bid; n = 27), thioridazine (25–150 mg bid; n = 30), and
haloperidol (2–15 mg/day; n = 27) on the QTc interval at
maximum serum concentration after dosing. Participants
were volunteer patients who were hospitalized for chronic
schizophrenia. Serial ECGs (approximately 30 per patient)
were recorded under fasting conditions and at the time of
estimated peak serum concentration for each study drug.
Patients took their randomly allocated antipsychotic alone
and also in the presence of a metabolic inhibitor to measure
the potential impact of P450 drug interactions on the serum
concentrations of the antipsychotic and on QTc
prolongation. A mean prolongation of QTc interval was
found for each antipsychotic agent tested, including
haloperidol, for which a dose-prolongation relationship was
detected. No patient had a QTc interval ≥ 500 ms. The QTc
prolongation effect of ziprasidone, at 20 ms, was
approximately 10 ms larger than the prolongation effects of
haloperidol, quetiapine, risperidone, and olanzapine, and
approximately 10 ms smaller than the effect of thioridazine.
Ziprasidone demonstrated no further QTc prolongation in
the presence of metabolic inhibition (ketoconazole, 200 mg
bid). A subsequent dose escalation study (Miceli et al 2003)
with 26 patients with schizophrenia or schizoaffective
disorder demonstrated that escalation of ziprasidone from
the maximum recommended clinical dose (160 mg/day) to
twice this dose (320 mg/day) produced only a marginal
additional mean increase in QTc prolongation. ECGs were
collected at baseline (drug-free condition) and at 5, 6
(estimated time of maximum serum concentration), and 7
hours post-dose on three steady-state drug administration
days (each day being the fourth consecutive day at a
particular dose). Relative to baseline, mean QTc interval
increases at doses of 40, 160, and 320 mg/day were
respectively 4.5, 19.5, and 22.5 ms. A further study (Miceli
et al 2002) has shown that IM ziprasidone (20 mg then 30 mg
injections, 4 hours apart; n = 31) and IM haloperidol (7.5 mg
then 10 mg injections, 4 hours apart; n = 27) cause
comparable mean increases to QTc intervals at maximum
observed serum/plasma concentrations for each injection
(respectively, 4.6 ms, and 12.8 ms for injections 1 and 2 of
ziprasidone, and 6.0 ms and 14.7 ms for injections 1 and 2
of haloperidol). No patient had a change from baseline QTc
≥ 75 ms, and no patient had a QTc interval ≥ 500 ms at any
time.
According to data on file with Pfizer, the manufacturer
of ziprasidone, there have been no confirmed reports of
torsades de pointes and no indications of increased
cardiovascular risk during clinical development trials ofNeuropsychiatric Disease and Treatment 2005:1(2) 97
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ziprasidone (> 2700 patient-years of ziprasidone treatment)
nor during post-marketing surveillance to date (> 500 000
patients having received ziprasidone). These are selected
populations however; patients with identified risk factors
for cardiac arrhythmia would have been excluded.
In summary, the evidence thus far suggests that the QTc
prolongation effect of ziprasidone is moderate, and that
when ziprasidone is appropriately prescribed, it does not
demonstrate clinically significant QTc effects. However,
clinicians should be aware of the risk factors for prolongation
of the QTc interval and should carry out a thorough
assessment of patient and family medical history before
deciding whether the benefits of ziprasidone treatment
outweigh the risks. (See Addressing the risk of QTc
prolongation below for further information.)
Adverse events associated with IM
ziprasidone
Results from two 24-hour, double-blind, fixed-dose IM
ziprasidone studies (2 mg versus 20 mg, Daniel et al 2001;
2 mg versus 10 mg, Lesem et al 2001), a 3-day, randomized,
open-label, flexible-dose, haloperidol-controlled IM
ziprasidone study (10 mg initial injection, then 5–20 mg
injections every 4–6 hours, as needed, mean daily dose
≈ 23 mg/day; Brook et al 2000), and a similar haloperidol-
controlled study (10 or 20 mg of IM ziprasidone initially,
then additional injections ≤ 40 mg/day as needed, mean daily
dose ≈ 26 mg/day; Brook et al 2001) that included a
sequential 6-week oral treatment phase, indicate that IM
ziprasidone is safe and well tolerated. In the two 24-hour
studies, common adverse events related to IM ziprasidone
treatment (reported in ≥ 10% of patients in any of the
ziprasidone groups) included headache, injection site pain,
nausea, and somnolence. Discontinuations due to
ziprasidone-related adverse events were uncommon (1.1%
of all patients receiving 2 mg injections and 0.6% of all
patients receiving higher doses). In the two haloperidol-
controlled studies, EPS occurred significantly less frequently
in ziprasidone patients than in haloperidol patients (p < 0.001
in both studies) during IM treatment. No adverse events
were reported to be statistically significantly more common
to IM ziprasidone treatment than to IM haloperidol treatment
in either study. The Brook et al (2000) study which, of the
two studies, reported more details of laboratory
abnormalities arising during IM treatment, reported that total
rates for laboratory abnormalities were similar (14% and
13% respectively), as were mean changes in QTc intervals
(< 3 ms for each group). The most common laboratory
abnormality for both IM ziprasidone and IM haloperidol
was elevated random glucose (> 1.2 × upper limit of normal)
and this occurred at the same frequency (10%) in both
groups. The report stated that there was no evidence of
hematologic or hepatic toxicity.
Adverse events associated with oral
ziprasidone
Evidence from 4- to 6-week randomized, double-blind,
placebo-controlled studies (Keck et al 1998, 2001; Daniel
et al 1999) and from 6- to 8-week randomized, double-blind
studies comparing ziprasidone to haloperidol, risperidone,
and olanzapine, respectively (data on file, Pfizer 2003;
Anonymous 2000; Simpson et al 2001; Addington et al
2002), indicate that oral ziprasidone is safe and well tolerated
and is not associated with adverse metabolic effects. The
total rate of treatment-related adverse events and the rate of
discontinuations due to such events in ziprasidone patients
(approximate rates 80% and 4%, respectively) in these
studies were similar to those of the placebo, haloperidol,
risperidone, and olanzapine patients. The most prevalent
adverse event that was statistically more common in
ziprasidone patients than in placebo patients was
somnolence (approximate rates respectively 14% and 7%;
p < 0.05). Compared with the rates of the majority of specific
adverse events in patients receiving haloperidol, risperidone,
or olanzapine (including somnolence, EPS, akathisia, and
weight gain) rates were significantly lower or not
significantly different in patients receiving ziprasidone.
Insomnia was an exception, being significantly more
common in ziprasidone patients than risperidone patients
(approximate rates respectively 25% and 12%; p < 0.01;
Addington et al 2002), but this result was not obtained in
the other studies. Total rates and rates of specific laboratory
abnormalities in ziprasidone patients were significantly
lower than or not significantly different from those in control
patients in these studies.
Three 6-week, open-label, blinded rater studies in which
patients experiencing suboptimal efficacy or tolerability
were switched to ziprasidone from conventional
antipsychotics (n = 108), olanzapine (n = 104), or risperidone
(n = 58) observed improvements in several measures of
physical health. Patients switched from olanzapine or
risperidone experienced statistically significant reductions
in body weight, BMI, triglycerides, and total cholesterol.
Patients switched from conventional antipsychotics or
risperidone experienced statistically significant reductions
in prolactin levels and EPS. No clinically significant changesNeuropsychiatric Disease and Treatment 2005:1(2) 98
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in ECG were observed in any patients and none exhibited a
QTc interval ≥ 500 ms.
A 1-year, double-blind, study (Arato et al 2002) in
inpatients with stable, chronic schizophrenia reported the
rates of adverse events associated with daily doses of 40 mg
(n = 72), 80 mg (n = 68), and 160 mg/day (n = 67) of
ziprasidone, and placebo treatment (n = 71). Questionnaires
screening for particular adverse events were not used. All
adverse events were either observed by the investigators or
voluntarily reported by subjects, which may have led to
underestimation of the actual frequency of adverse events.
The total rates of all laboratory abnormalities and of all other
adverse events were similar across the four groups, as were
the rates of discontinuation due to treatment-related events.
Table 1 summarizes these results, and provides the
frequencies of the most common adverse events (events
experienced at rates ≥ 10% in one or more groups); namely,
insomnia, agitation, anxiety, akathisia, depression, and
headache.
Among the less frequent adverse events, the following
were experienced at moderate rates (< 10% in all four groups
but > 5% in one or more ziprasidone groups): diarrhoea,
hypertension, weight loss, rash, vomiting, EPS, asthenia,
tooth disorder, respiratory tract infection, bronchitis,
pharyngitis, tremor, accidental injury, infection, and flu
syndrome. All remaining events occurred at low rates in all
the ziprasidone groups (≤ 3% for the first three events listed,
and ≤ 4% for the rest): tachycardia, increased salivation, dry
mouth, somnolence, dyskinesia, dyspepsia, and nausea. Of
all the reported adverse events, only asthenia was statistically
more frequent (p < 0.05) in any ziprasidone group (the
160 mg/day group, in which the rate was 9%) compared
with the placebo group (in which the rate was 0%). Serious
adverse events that were classed as treatment-related were
experienced by one placebo patient and four patients on
ziprasidone (40 mg/day). One ziprasidone patient
experienced EPS, asthenia, dehydration, and hypotension
on day 6; another had a recurrence of acute dystonia on day
13; a third ziprasidone patient had vomiting and cardiac
insufficiency on day 2; and the fourth had a grand mal
seizure also on day 2.
Most of the laboratory abnormalities were isolated
reports in single patients. Changes in blood pressure and
pulse rate and changes in hematological, renal, liver, and
hormonal measures were all clinically insignificant and no
more frequent in ziprasidone patients than in placebo
patients. Median serum prolactin levels decreased in all
treatment groups (1–4.25 ng/mL). No opthalmological
abnormalities were observed. No clinically significant
ECG abnormalities and QTc interval changes were
observed in the ziprasidone groups. No patient had a QTc
interval > 500 ms.
Table 1 Frequency over one year of discontinuations, laboratory (lab) abnormalities, and treatment-related adverse events (AE) in
patients treated with ziprasidone or placebo
Ziprasidone Ziprasidone Ziprasidone
40 mg/day 80 mg/day 160 mg/day Placebo
n% n% n% n%
Reason for discontinuation
Sample size 72 68 67 71
Total discontinued 42 58 39 57 37 55 61 86
Lab abnormality 0 0 1 1 2 3 1 1
AE 7 10 7 10 5 7 11 15
Relapse 27 38 21 31 23 34 43 61
Other 8 11 10 15 7 10 6 8
Median duration of treatment 200 days 149 days 271 days 72 days
Any lab abnormality at any time
a 14 20
b 18 26
c 15 21
d 13 18
e
Any AE at any time 52 72 50 74 47 70 54 76
Percentage rates of particular AEs occurring in ≥ 10% of patients in any treatment group
Insomnia 28 28 45 31
Agitation 13 12 10 18
Anxiety 11 10 13 17
Akathisia 10 9 12 6
Depression 8 6 10 6
Headache 4 7 10 6
a All participants who underwent lab tests at baseline and within 6 days of the last treatment day.
b n = 70, c n = 70, d n = 71, e n = 74.Neuropsychiatric Disease and Treatment 2005:1(2) 99
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Ziprasidone and placebo patients were indistinguishable
in terms of changes (small mean improvements) from
baseline scores on the Simpson-Angus Scale (a measure of
EPS; Simpson and Angus 1970), the Barnes Akathisia Scale
(Barnes 1989), and the Abnormal Involuntary Movements
Scale (Guy 1976b). Rates of concomitant use of anti-
cholinergic medication at some time during the study were
17%, 13%, 19%, and 13% for the 40, 80, and 160 mg/day
ziprasidone groups, and the placebo group, respectively
(nonsignificant differences). Beta-blocker use was negligible
in all groups.
In a 28-week, flexible dose, double-blind study (Hirsch
et al 2002), rates of the majority of specific adverse events
were similar or lower in patients receiving ziprasidone
(80–160 mg/day; n = 148) compared with patients receiving
haloperidol (5–15 mg/day; n = 153). The percentages of
patients who experienced at least one adverse event in the
two groups were 77% and 85%, respectively. Insomnia was
a common adverse event in both groups (16% and 18%,
respectively). Akathisia was significantly less common
(p < 0.01) in ziprasidone patients (5%) than in haloperidol
patients (16%). Body weight changes were small and similar
in the two groups. Few adverse events were serious enough
to result in discontinuation. Laboratory abnormalities were
experienced at similar rates in ziprasidone and haloperidol
patients (38% and 34%, respectively). Mild postural
hypotension was experienced by one ziprasidone patient.
Otherwise, QTc interval, blood pressure, pulse rate, liver
function, and hematologic assessments revealed no clinically
significant treatment effects in either group.
Two double-blind, flexible-dose extension studies
comparing ziprasidone to olanzapine (Simpson et al 2002)
and ziprasidone to risperidone (Addington et al 2003) and
a randomized, double-blind 28-week study comparing
ziprasidone with olanzapine (Kane et al 2003) provide
additional information on the relative long-term safety and
tolerability of ziprasidone. While caution is needed when
interpreting the two extension studies, because patients
whose medication was ineffective and/or intolerable in the
preceding short-term phase did not participate in the
extension phase, the longer-term data obtained indicates that
the rates of most of the more common (mild or moderate)
adverse events experienced by patients receiving
ziprasidone, olanzapine, or risperidone were not
significantly different. Adverse effect frequencies and
laboratory abnormalities that emerged between ziprasidone
and olanzapine in these longer-term studies, which were
statistically significant, are shown in Table 2. The table also
includes differences between ziprasidone and risperidone
that were likely to have been statistically significant but for
which significance values were not provided in the original
report.
Summary of safety and efficacy of
ziprasidone
Evidence to date demonstrates the efficacy of ziprasidone
in the management of acute psychotic agitation, in the
treatment of acute exacerbations and in maintenance
treatment and relapse prevention in patients with
schizophrenia or schizoaffective disorder. Its efficacy is
superior to that of placebo, and comparable to that of
risperidone and haloperidol. Its efficacy compared with
olanzapine remains to be clarified, and may depend on the
dosing range permitted for each drug, and the rate of titration
of ziprasidone.
Ziprasidone’s side effect profile may prove to be safer
and more acceptable to patients compared with other
antipsychotic agents. Ziprasidone does not appear to cause
the metabolic syndrome (weight gain and elevations in
glucose, insulin, cholesterol, and lipid levels) associated to
varying degrees with other atypical antipsychotic
medications. It also appears to be less likely than haloperidol
and risperidone to cause EPS and hyperprolactinemia.
Ziprasidone has been found to lengthen the cardiac QTc
interval. As yet there is insufficient long-term data to
determine the relative risks of ziprasidone versus other
antipsychotic medications in causing life-threatening cardiac
arrhythmia. Clinicians should be aware of the risk factors
for prolongation of the QTc interval and should obtain a
patient and family medical history before deciding whether
a trial with ziprasidone treatment is appropriate (see below).
Recommendations for the
practical, clinical use of
ziprasidone
Addressing the risk of QTc
prolongation
Measuring an individual patient’s mean baseline and mean
post-baseline QTc intervals is not a clinically useful method
of monitoring or managing the QTc prolongation effects of
ziprasidone or other antipsychotic agents. An individual’s
QTc interval varies considerably over the course of a day,
which means that mean measurements will have large
standard errors and will therefore be unreliable forNeuropsychiatric Disease and Treatment 2005:1(2) 100
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Table 2 Safety/tolerability differences emerging in three longer-term studies (28–44 weeks) comparing ziprasidone to olanzapine
or to risperidone
Safety/tolerability results that favored ziprasidone (40–80 mg bid) over:
Olanzapine 5–15 mg bid Olanzapine 10–20 mg bid Risperidone 3–5 mg bid
6-month, blinded extension for 28-week, randomized, double-blind 44-week, blinded extension for
completers of a 6-week, randomized, study (Kane et al 2003) completers of 8-week, randomized,
double-blind study (Simpson et al double-blind study (Addington et al
2002
a) 2003
b)
Overall rates of laboratory (no significant differences) NR Zip 57% 
abnormalities Risp 96%
Group difference p < 0.001
Weight Zip ≈ –3 lbs p < 0.001 Zip –2.5 lbs (p not given) Zip  ≈ +1 lb 
Olanz ≈ +10 lbs p < 0.001 Olanz +6.7 lbs (p not given) Risp ≈ +8 lbs
Group difference p < 0.001 Group difference p < 0.001 (p not given)
Body mass index change Zip no change ns NR NR
Olanz mean gain p < 0.001
Group difference p < 0.001
Insulin Zip  +1 µ/mL ns NR NR
Olanz +2 µ/mL p < 0.01
Group difference ns
Glucose Zip  +2 mg/dL ns Zip 0 mg/dL ns NR
Olanz +5 mg/dL p < 0.05 Olanz +5 mg/dL (p not given)
Group difference ns Group difference p < 0.001
Prolactin  NR (no significant differences) Zip –8 ng/mL
Risp +26 ng/mL (p not given)
Total cholesterol Zip  –1 mg/dL ns Zip –12 mg/dL (p not given) NR
Olanz +13 mg/dL p < 0.05 Olanz +3 mg/dL (p not given)
Group difference ns Group difference p < 0.001
HDL cholesterol  NR Zip +1 mg/dL (p not given) NR
Olanz –3 mg/dL (p not given)
Group difference p < 0.001
LDL cholesterol  Zip +9 mg/dL ns Zip –10 mg/dL (p not given) NR
Olanz +17 mg/dL p < 0.05 Olanz +2 mg/dL (p not given)
Group difference ns Group difference: p < 0.01
Triglycerides NR Zip  –20 mg/dL ( p not given) NR
Olanz +32 mg/dL (p not given)
Group difference p < 0.001
Hepatic enzymes Zip no change in AST level  NR NR
Olanz increased AST p < 0.001
Group difference p < 0.05
Zip no change in ALT level
Olanz increased ALT p < 0.01
Group difference p < 0.01
Rates of specific adverse Zip vs olanz:   Zip vs olanz:  Zip < risp: 
effects Weight gain 0% vs 17% p < 0.01 Weight gain 2% vs 13% p < 0.001 Increased salivation (≈ 5 times lower)
Increased appetite 3% vs 7% p < 0.05 Akathisia (≈ 3 times lower)(actual rates
and p not given)Neuropsychiatric Disease and Treatment 2005:1(2) 101
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comparison. Furthermore, group studies indicate that the
extent of QTc prolongation does not appear to be linearly
related to the potential for cardiac arrhythmia problems
(Morganroth 1993).
As when any new antipsychotic medication is being
considered, the patient should receive medically needed
physical assessments, laboratory tests, and other evaluations
according to standards of good clinical practice (CPA 1998;
APA 2004). In addition to obtaining the patient’s medical
history, the clinician should establish whether there is a
family history of syncope or sudden unexplained death, as
these may indicate congenital long QT syndrome.
Clinicians should be aware of the FDA guidelines on
the use of ziprasidone. Table 3 provides a list of risk factors
for QTc prolongation that have implications for the use of
ziprasidone. The table also provides possible actions
regarding decisions concerning ziprasidone treatment.
Additional risk factors for QTc interval prolongation
have been identified; these include the female sex as well
as endocrine/metabolic abnormalities, such as obesity,
diabetes, and thyroid abnormalities (Rautaharju et al 1992;
Carella et al 1996; Brown et al 2001; Vieweg 2002).
Clinicians should use their own judgment in weighing the
potential benefits and risks of ziprasidone in these cases,
and operate within their personal comfort zone. In the
opinion of the authors, these additional risk factors are not
themselves compelling reasons to rule out ziprasidone
treatment. If clinicians opt to obtain an ECG, a QTc interval
> 450 ms would be a contraindication for treatment with any
drug that prolongs the QTc interval.
When to consider a trial with
ziprasidone
Given the current clinical data available, the authors suggest
that ziprasidone be considered as a first-line antipsychotic
medication in both the acute and long-term maintenance
treatment of people with schizophrenia, schizoaffective
disorder, or schizophreniform disorder. At this time, due to
a lack of information, it would be premature to suggest using
ziprasidone in treatment-resistant patients, those patients
stabilized on clozapine, or in elderly patients with complex
medical problems. As discussed above, patients with risk
factors for QTc prolongation listed in Table 3 should not be
prescribed ziprasidone.
According to Canadian Clinical Practice Guidelines
(CPA 1998), patients should have regular reassessments of
their symptoms, treatment regime (including psychosocial
aspects as well as dosing and side effects of medications),
and functional recovery. In stable patients, these
Table 2 continued
Safety/tolerability results that favored ziprasidone (40–80 mg bid) over:
Olanzapine 5–15 mg bid Olanzapine 10–20 mg bid Risperidone 3–5 mg bid
Abnormal movements Baseline to end point: Largest changes from baseline (No significant group differences on
Zip AIMS –0.3 (p not given) Zip: AIMS +0.5 (p not given) AIMS, BAS, MDBS, or SAS)
Olanz AIMS –0.8 (p not given) Olanz: AIMS +0.2 (p not given)
Group difference p < 0.05 Group difference p = 0.01
(no significant group differences on Zip: BAS +0.3 (p not given)
BAS or ESRS scores) Olanz: BAS +0.2 (p not given)
Group difference p < 0.05
Zip: SAS +0.6 (p not given)
Olanz: SAS –0.0 (p not given)
Group difference p < 0.001
Rates of specific adverse Zip vs olanz: Zip vs olanz: Zip > risp:
effects EPS 11% vs 4% p < 0.05 Insomnia 22% vs 7% p < 0.001 Insomnia (≈ 3 times higher)(actual
Tremor 8% vs 3% p < 0.05 Vomiting 9% vs 4% p < 0.05 rates and p not given)
Anorexia 3% vs 0% p < 0.05
Dystonia 0% vs 2% p < 0.05
Hypotension 0% vs 2% p < 0.05
Aggravated psychosis
c 4% vs 1%
p < 0.05
a Changes from start of 6-week phase (Simpson et al 2001) to end of extension phase (last observation carried forward, unless otherwise stated).
b Changes from start of 8-week phase (Addington et al 2002) to end of extension phase (last observation carried forward, unless otherwise stated).
c Cases of aggravated psychosis that led to discontinuation of treatment.
Abbreviations: AIMS, Abnormal Involuntery Movements Scale; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BAS, Barnes Akathisia Scale; EPS,
extrapyramidal symptoms; ESRS, Extrapyramidal Symptom Rating Scale; HDL, high-density lipoprotein; LDL, low-density lipoprotein; MDBS, Movement Disorder
Burden Scale; NR, not reported; ns, not significant; olanz, olanzapine; risp, risperidone; SAS, Simpson-Angus Scale; zip, ziprasidone.Neuropsychiatric Disease and Treatment 2005:1(2) 102
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reassessments should be approximately every 6 months.
Should patient recovery be less than optimal, consideration
can be given to changing antipsychotic medication.
Ziprasidone may be considered for treatment optimization
in patients who have responded to another antipsychotic
medication but who either have clinically relevant residual
symptoms or clinically significant side effects, eg,
problematic weight gain or other problematic metabolic
symptoms. In addition to its use as a first-line oral treatment
or as an optimizing agent, IM ziprasidone can be used in
patients presenting with psychosis-related acute agitation
in emergency room settings.
Dosing: initiating and switching
Whenever ziprasidone is prescribed, steps must be taken to
ensure that patients are not exposed to other prescription
drugs or over-the-counter medications known to prolong
the QTc interval. Table 4 provides a list of common
medications with QTc prolongation action. A more complete
up-to-date list of all such agents is available at http://
www.qtdrugs.org.
Initiating oral ziprasidone treatment in
patients naive to antipsychotic drugs
It is important to the future adherence of medication that
patients’ first experiences of antipsychotic medication is
agreeable (ie, minimal experiences of unpleasant side
effects). Patients with first-episode psychosis (FEP) tend to
be more sensitive to the therapeutic effects and adverse
effects of antipsychotic medication. Although there are
limited data relevant to initiating ziprasidone treatment in
drug-naive patients to date, the following suggestions are
made for the initiation of ziprasidone therapy in drug-naive
patients, based on the group consensus:
•2 0  mg bid on day 1;
•4 0  mg bid for days 2–5;
• Maintain at 40 mg in the morning; titrate the evening
dose up to the minimum effective therapeutic dose,
leaving enough time between dose increments to evaluate
symptom response (approximately 6–10 days);
• Adjust timing and balance of the morning and evening
doses in response to problems with somnolence/
insomnia;
• Total daily dose should not usually exceed 120 mg in
FEP patients. Doses above 120 mg/day (up to the
maximum total daily dose of 160 mg) should only be
considered in FEP patients in the presence of an initial
but suboptimal response and in the absence of significant
side effects;
• Concurrent anticholinergic treatment is not usually
necessary.
Agitation is a common problem in drug-naive patients
receiving low doses of ziprasidone. See section on the
management of side effects for suggestions on how this
problem can be managed.
Use of IM ziprasidone treatment in
cases of acute exacerbation of agitation
Injectable ziprasidone may be used when necessary in the
treatment of acute psychosis.
Table 3 Risk factors for QTc interval prolongation and implications regarding the use of ziprasidone
Risk factor Suggestion
Diagnosed or suspected congenital long QT syndrome Ziprasidone treatment should be avoided
Personal or family history of syncope Ziprasidone treatment should be avoided
Family history of sudden unexplained death Ziprasidone treatment should be avoided
Cardiac disease, with a history of cardiac arrhythmias, myocardial Ziprasidone treatment should be avoided
ischemia, or congestive heart failure
Bradycardia Ziprasidone treatment should be avoided
Central nervous system lesions (eg, stroke, infection, trauma, Ziprasidone treatment should be avoided
Parkinson’s disease)
Interaction with other drugs that can prolong the QTc Ziprasidone should not be used if exposure to other drugs that
interval (see Table 4) prolong the QTc interval can not be avoided
Electrolyte imbalance (hypokalemia or hypomagnesemia) Ziprasidone should not be used unless the electrolyte imbalance is
corrected
Use of diuretics, kidney disease Patients at risk of electrolyte imbalances should have baseline
measurements and regular monitoring of potassium and
magnesium levelsNeuropsychiatric Disease and Treatment 2005:1(2) 103
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• A starting dose of 20 mg IM (10 mg IM in drug-naive
patients) is suggested.
• The maximum dose should be 40 mg/24 hours for
≤ 3 days.
• Concomitant benzodiazepines can be used.
• Prophylactic anticholinergic medications are not usually
necessary.
Switching to ziprasidone from current
treatment with another atypical
antipsychotic agent
Data from current studies (Weiden, Simpson, et al 2003)
showed no difference in outcome between different
switching strategies. It is suggested that a cross-over strategy
be used (ie, the current drug is gradually decreased while
ziprasidone is begun and titrated upward). Duration of a
typical cross-over period would be in the order of 1–2 weeks,
but this needs to be individualized and based on patient
tolerance and on the patient setting (inpatient or outpatient).
Patients should not be maintained on intermediate doses of
both medications.
Available data suggest a starting dose of ziprasidone of
80 mg/day (given as 40 mg bid) for the first two days,
followed by flexible dosing. Most patients requiring
maintenance treatment respond at doses in the range
80–160 mg/day. Most patients requiring treatment of an
acute exacerbation respond at doses in the range
120–160 mg/day. There is some evidence that rapid titration
to doses in the range 120–160 mg/day results in earlier
improvements in symptoms in cases of acute exacerbation
as well as better prevention of relapse in patients requiring
maintenance treatment compared with doses ≤ 80 mg/day
(Murray et al 2003). To date, there is little evidence of greater
improvement in symptom control using doses above
160 mg/day (Anonymous 2000; Davis and Chen 2004).
Switching to ziprasidone from current
treatment with a conventional
antipsychotic agent
For patients being switched from an oral conventional
antipsychotic, a cross-over strategy is similarly suggested,
as described above. (Suggested dosing of ziprasidone is also
as described above for patients being switched from another
atypical agent.) If the patient was previously taking
anticholinergic medication, this anticholinergic medication
should be continued at the same dose for 2 weeks after
discontinuation of the conventional antipsychotic to reduce
Table 4 Drugs with generally accepted QTc interval
prolongation action, organized by class of drug
Usage/Class of drug Drug names 
Alpha1-blocker Alfuzosin
ADHD Atomoxetine, methylphenidate
Antianginal Bepridila
Antiarrhythmic Amiodarone, disopyramide, dofetilide,
flecainide, ibutilide, procainamide,
quinidine, sotalol
Sympathomimetic (asthma) Salmeterol
Antibiotic Azithromycin, clarithromycin,
erythromycin, fluconazole, gatifloxacin,
grepafloxacin, ketoconazole, levofloxacin,
moxifloxacin, sparfloxacin, telithromycin
Anticancer Arsenic trioxide, tamoxifen
Anticonvulsant Felbamate, fosphenytoin
Antidepressant Venlafaxine
Antiemetic Ondansetron
Antifungal Voriconazole
Antihistamine Astemizole,a terfenadinea
Antihypertensive Isradipine, moexipril/hydrochlorothiazide,
nicardipine
Antiinfective Pentamidine
Antimalarial Chloroquine, halofantrine
Antimania Lithium
Antinausea Dolasetron, domperidone, droperidol,
granisetron
Antipsychotic Chlorpromazine, clozapine, haloperidol,
mesoridazine, pimozide, quetiapine,
risperidone, thioridazine
Antiviral Amantadine, foscarnet
Appetite suppressant Fenfluramine, phentermine, sibutramine
Bronchodilator Salbuterol, ephedrine, levalbuterol,
metaproterenol, terbutaline
Catecholamine Dobutamine, epinephrine, isoproterenol
Decongestant Ephedrine, phenylephrine,
phenylpropanolamine, pseudoephedrine
Diuretic Indapamide
Dopaminergic (Parkinson’s) Amantadine
Endocrine Octreotide
Gastrointestinal stimulant Cisapride,a erythromycin
Immunosuppressant Tacrolimus
Muscle relaxant Tizanidine
Opiate agonist Levomethadyl, methadone
Sedative Chloral hydrate, droperidola
Uterine relaxant Ritodrine
Vasoconstrictor Epinephrine, midodrine, norepinephrine,
phenylephrine
Vasodilator Vardenafil
Other Cocaine
A more complete up-to-date list of all such agents is available at www.qtdrugs.org.
a These medications are no longer available in Canada but may still be available
elsewhere.Neuropsychiatric Disease and Treatment 2005:1(2) 104
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the risk of withdrawal dyskinesia. Over the next 2–4 weeks,
the anticholinergic medication should be gradually tapered
and discontinued.
Before being switched to ziprasidone, patients taking
depot conventional antipsychotics given intramuscularly
should be reassessed with a focus on the reasons for the use
of long-acting medication. If nonadherence to oral
medication is considered likely, the patient should not be
switched to ziprasidone at this time. Patients taking depot
conventional antipsychotics and an oral anticholinergic
medication who are assessed as suitable candidates for a
trial with oral ziprasidone need to be continued on their
anticholinergic medication for at least 12 weeks following
the cessation of the conventional antipsychotic. The
anticholinergic drug should not be stopped abruptly as
withdrawal has been documented.
Management of side effects of
ziprasidone
Sleep disturbance
Somnolence during the day can be managed by splitting
the bid dosing into a lower dose in the morning and a higher
dose in the evening. Conversely, insomnia at night can be
managed by splitting the dosing into a higher dose in the
morning and a lower dose in the evening and/or by adjusting
the timing of the evening dose.
Agitation/akathisia during initiation of
ziprasidone in patients naive to
antipsychotic medication
Agitation needs to be differentiated from akathisia. Agitation
is a common problem when drug-naive patients are receiving
low doses of ziprasidone. If the symptoms are due to
agitation, suggested treatment is an increased dose of
ziprasidone and/or short-term use of benzodiazepines, not
treatment with beta-blockers. Agitation usually settles within
2–3 days of an increase in dose of ziprasidone. In situations
in which the symptomatology is unclear, small doses of
medium-acting benzodiazepines (such as clonazepam) can
be considered.
Important aspects of monitoring
of ongoing treatment with
ziprasidone
As part of the management of patients with schizophrenia
and related psychotic disorders, all should receive good
medical care, including yearly physical medical exam-
inations and 6-monthly assessment of symptoms,
functioning, and side effects. Table 5 provides a summary
of features to assess at baseline and at subsequent
assessments, in order to evaluate ziprasidone treatment.
Long-term monitoring should be individualized according
to patient history and the baseline assessment. No special
long-term monitoring is required for patients on ziprasidone
except for those who were experiencing medical problems
prior to ziprasidone treatment. For example, a patient with
elevated glucose and lipid plasma levels related to a previous
Table 5 Patient characteristics to assess at baseline and at
6-monthly follow-up assessments
Target symptoms 
Positive symptoms Hallucinations, delusions, behavioral
abnormalities, disorganization
Negative symptoms Social isolation, reduced motivation,
reduced speech, reduced pleasure
Mood Low mood, suicidal thoughts
Cognition Memory problems, attention deficits,
concentration difficulties
Target aspects of daily life 
Personal care Poor hygiene (washing, bathing,
grooming), appearance, clothing
Social Most of day alone, little interaction with
friends/family
Housing Frequent moves, living on the street
Nutrition Poor diet, frequently missing meals,
excessive consumption of high-fat fast
foods
Vocational Difficulties finding and/or keeping up with
job/school
Organizational/social Difficulty connecting with community
supports
Overall Recurring need for hospitalization
Quality of life As perceived by informants, as perceived
by patient
Target side effects 
Movements Akathisia, parkinsonism, tardive
dyskinesia, tremor
Cardiovascular Hypotension
Endocrine
a Gynecomastia, galactorrhea,
oligomenhorrhea, amenhorrhea
Metabolic
a Weight gain, lipid elevation, glucose
intolerance/diabetes
Sexual functioning Loss of libido, impotence
Emotional/Cognitive Flattened affect, difficulties with
concentration and memory
Sleep Sedation, insomnia
a Monitor if these were problems prior to treatment with ziprasidone.Neuropsychiatric Disease and Treatment 2005:1(2) 105
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antipsychotic medication should be periodically monitored
to see if these problems are reversing. A patient with kidney
disease should be monitored to assess whether potassium
and magnesium levels are within the normal range.
Nonadherence to antipsychotic
medication
The biggest challenge to the effectiveness of antipsychotic
medication in prevention of relapse may not be efficacy
(Marder and May 1986; Wyatt 1991) but high rates of
nonadherence (Fenton et al 1997). Patients prescribed
medications for treatment of schizophrenia report a median
nonadherence rate of 55% (range 24%–88%) within two
years (Young et al 1986; Fenton et al 1997). Forty percent
stop within one year and about 75% do so within two years.
In cases of FEP, poor medication adherence ranges from
33% to 44%, with more than half (53%) interrupting their
medication at least once within two years (Verdoux et al
2000). The likelihood of relapse after treatment of FEP is at
least sixfold higher if the patient stops antipsychotic
medication (Robinson et al 1999). A significantly more
episodic course and higher rates of readmission to hospital
are also reported for FEP patients with poor medication
adherence (Verdoux et al 2000).
Some of the correlates of nonadherence can be
considered unintentional (eg, due to intolerable side effects
from medications, or unwieldy medication regimens).
However, a substantial proportion of patients intentionally
stop taking medication because of lack of insight about the
nature of their illness, refusal to acknowledge the possibility
of relapse, or other health-related belief systems. Poor
therapeutic alliance, lower occupational status, alcohol
abuse/dependence, the initial intensity of delusions,
suspiciousness, and persecution are also predictive of
nonadherence to medication in FEP (Verdoux et al 2000;
Perkins 2002). Poor adherence to medication early in
treatment also predicts poor adherence in the longer term
(Lacro et al 2002). Focus groups conducted with patients,
families, and clinical staff suggest the role of the following
additional factors related to nonadherence: peer pressure,
“feeling different”, misattribution of symptoms to side
effects of medications, and cultural attitudes, particularly
among young patients. Designing interventions to improve
adherence to medication very early in the course of illness
is crucial to preventing relapse. Availability of medications
whose side effects are more tolerable to patients would aid
such endeavors.
To promote adherence to medication, clinicians should
fully explore patients’ views about their illness and patients’
attitudes and behaviors regarding their medications
(Zygmunt et al 2002). Identifying patients’ goals and
aspirations and relating them to treatment outcomes has been
found to increase treatment adherence (Kemp et al 1998).
Patients should be offered group educational sessions to
provide information on the nature of their illness and its
treatment, and to discuss strategies to resolve common
problems with treatment adherence. Patients should be
encouraged to report side effects and clinicians should be
responsive in trying to diminish or eliminate side effects.
When appropriate, family members should also be offered
education to foster their involvement in helping patients
adhere to their treatment regimes, and to provide family
members with advice and support in coping with patients’
illnesses (Dixon and Lehman 1995; Dixon et al 2000;
Addington et al 2001). Further information regarding factors
affecting adherence to antipsychotic medications can be
found in the American Psychiatric Association treatment
guidelines on schizophrenia (APA 2004).
Adherence to treatment with
ziprasidone
The relatively low incidence of EPS and the low risk for
weight gain associated with ziprasidone may make
ziprasidone more acceptable at the outset and as treatment
continues for many patients. As discussed above, when
ziprasidone is prescribed to FEP patients, clinicians should
pay particular attention to quickly addressing agitation and
sleep disturbances (insomnia, somnolence) to which drug-
naive patients are especially susceptible, to avoid early
abandonment of ziprasidone treatment.
Conclusion
Ziprasidone is an effective acute and long-term maintenance
treatment option for patients with schizophrenia,
schizoaffective disorder, and schizophreniform disorder. It
is safe when used with patients who do not have risk factors
for QTc prolongation. Ziprasidone is less likely than
haloperidol to cause EPS and hyperprolactinemia.
Ziprasidone does not appear to cause the metabolic
syndrome (weight gain and elevations in glucose, insulin,
cholesterol, and lipid levels) associated to varying extents
with other atypical antipsychotics. It also appears to be less
likely than risperidone to cause hyperprolactinemia.
Common adverse events associated with ziprasidoneNeuropsychiatric Disease and Treatment 2005:1(2) 106
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treatment include agitation and sleep disturbances. It is well
tolerated if these problems are managed appropriately (as
described above). Ziprasidone can be considered for patients
currently receiving other antipsychotic medication if their
response to their current medication is suboptimal and/or
they are experiencing problematic side effects. It can also
be considered for FEP patients.
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